GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomics Biopharma Ltd (ASX:BBM) » Definitions » Cash Flow for Lease Financing

Biomics Biopharma (ASX:BBM) Cash Flow for Lease Financing : A$ Mil (TTM As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Biomics Biopharma Cash Flow for Lease Financing?

Biomics Biopharma's Cash Flow for Lease Financing for the six months ended in . 20 was A$0.00 Mil. Biomics Biopharma does not have enough years/quarters to calculate the Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in . 20.

Compared with last quarter (A$0.00 Mil in . 20 ), Biomics Biopharma's Cash Flow for Lease Financing remained the same in . 20 (A$0.00 Mil).


Biomics Biopharma Cash Flow for Lease Financing Historical Data

The historical data trend for Biomics Biopharma's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomics Biopharma Cash Flow for Lease Financing Chart

Biomics Biopharma Annual Data
Trend
Cash Flow for Lease Financing

Biomics Biopharma Semi-Annual Data
Cash Flow for Lease Financing

Biomics Biopharma Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.



Biomics Biopharma Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Biomics Biopharma's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomics Biopharma (ASX:BBM) Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.

Biomics Biopharma (ASX:BBM) Headlines

No Headlines